

92. The method of claim 1 wherein the nucleic acid is administered *ex vivo*.
93. The method of claim 1 wherein the nucleic acid is administered *in vivo*.
94. The method of claim 1 wherein the nucleic acid is administered to a human.
95. The method of claim 1 wherein the nucleic acid is administered to livestock, poultry or dog or cat.

96. A method for delivering nucleic acid to cells in tissue of interest, comprising:
administering to the tissue a phosphodiesterase ^{inhibitor} compound and exogenous nucleic acid.

11/2 (no int basis)

REMARKS

Claims 70-96 have been added. No new matter has been added by virtue of the new claims. For instance, support for the new claims appears e.g. at page 4, lines 5-25, page 6, lines 16-17 and the original claims of the application, including original claims 2-30.


In response to the Restriction Requirement, Applicants elect Group I, which includes claim 1, as that Group is defined in the Office Action.

An Information Disclosure Statement is being submitted under separate cover.

Early consideration and allowance of the application are earnestly solicited.

K. Donahue et al.
U.S.S.N. 09/977,865
Page 5

Respectfully submitted,

A handwritten signature in black ink, appearing to be 'P. Corless', written in a cursive style.

Peter F. Corless (Reg. 33,860)
EDWARDS & ANGELL, LLP
P.O. Box 9169
Boston, MA 02209
(617) 439-4444